Technology-driven precision medicine company Variantyx secures $41.5 million in funding
The funding round is led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners and Pitango HealthTech
FRAMINGHAM, Mass., February 14, 2022 /PRNewswire/ — Variantexa technology-driven precision medicine company that provides advanced genomic testing for the rare genetic disease, reproductive health and precision oncology markets, today announced that it has been awarded $41.5M in financing. Series C-2 funding round, led by New Era Capital Partners and including Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners and Pitango HealthTech, will be used to fuel company growth and launch solutions newly developed in all markets, with a focus on precision oncology.
Variantyx is poised to capitalize on the rapidly growing global precision oncology market with access to North America and Europe, respectively the largest and fastest growing regions for oncology spending.
Variantyx’s proprietary whole genome sequencing and analysis platforms enable healthcare providers and their patients to better understand a person’s genetic makeup, leading to unparalleled diagnostic capabilities and treatment recommendations. improved personalized treatment. The company’s precision oncology solution will use multiple genomic technologies to analyze and identify unique genetic alterations in a patient’s tumor to help predict their response to various therapies, optimize management and provide insights on prognoses and clinical trials.
“The funding is a great show of confidence in the company,” said Haim Neerman, CEO of Variantyx. “This allows us to extend our diagnostic solutions to a wider range of customers so that medical care can become more personalized. Variantyx’s growth has been exponential, and we can’t wait to share the disruptive new products we have in the works.
This marks the continuation of the long-standing relationship between Variantyx and New Era Capital Partners. “Variantyx is changing the way precision medicine is practiced with the most advanced platform on the market, which can detect a range of genetic findings through whole genome analysis. It makes a huge difference in the diagnostics and treatment market,” says Gideon Argov, Managing Partner at New Era Capital Partners. “We are excited to help take the company to the next level, bringing personalized medicine to the mainstream.”
Variantyx is a technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx enable clinicians and patients to better understand a person’s genetic makeup, leading to unparalleled diagnostic capabilities and improved personalized treatment recommendations. For more information, please visit www.variantyx.com.